Agilent Technologies
A · Life Sciences Tools & Services
$173.07
0.5%Charles River Laboratories
CRL · Life Sciences Tools & Services
$345.37
1.7%The short version
- Agilent Technologies is the larger business, with $6.9B of revenue in fiscal 2025 against $4.0B for Charles River Laboratories, about 1.7 times as much.
- Agilent Technologies grew revenue faster (6.7%, against −0.9%).
- Agilent Technologies kept more of each dollar of sales as operating profit (21.3% operating margin, against 0.6% operating margin).
- Agilent Technologies turned more of its sales into free cash flow (16.6% FCF margin, against 12.9% FCF margin).
- Agilent Technologies earned a higher return on the capital invested in it (16.5%, against 0.4%).
| Latest fiscal year | A · FY25 | CRL · FY25 |
|---|---|---|
| Size | ||
| Market cap | $49.0B | $16.6B |
| Revenue | $6.9B | $4.0B |
| Free cash flow | $1.2B | $518M |
| Net income | $1.3B | −$144M |
| Growth | ||
| Revenue growth | 6.7% | −0.9% |
| 5-year growth | 5.4% | 6.6% |
| Share count change | −2.1% | −4.0% |
| Profitability | ||
| Gross margin | 52.4% | — |
| Operating margin | 21.3% | 0.6% |
| Net margin | 18.8% | −3.6% |
| FCF margin | 16.6% | 12.9% |
| Return on capital | 16.5% | 0.4% |
| Return on equity | 20.6% | −4.4% |
| Balance sheet | ||
| Net debt | $1.6B | $1.9B |
| Net debt / EBITDA | 0.9x | 4.5x |
| Dividends and buybacks | $707M | $361M |
| Valuation & quality | ||
| P/E | 34.1x | — |
| Piotroski F-score | 5 | 4 |
FY16
A $4.2B
CRL $1.7B
FY17
A $4.5B
CRL $1.9B
FY18
A $4.9B
CRL $2.3B
FY19
A $5.2B
CRL $2.6B
FY20
A $5.3B
CRL $2.9B
FY21
A $6.3B
CRL $3.5B
FY22
A $6.8B
CRL $4.0B
FY23
A $6.8B
CRL $4.1B
FY24
A $6.5B
CRL $4.1B
FY25
A $6.9B
CRL $4.0B
A
CRL
FY16
A 14.6%
CRL 14.1%
FY17
A 18.1%
CRL 15.5%
FY18
A 18.4%
CRL 14.6%
FY19
A 18.2%
CRL 13.4%
FY20
A 15.9%
CRL 14.8%
FY21
A 21.3%
CRL 16.7%
FY22
A 23.6%
CRL 16.4%
FY23
A 19.8%
CRL 15.0%
FY24
A 22.9%
CRL 5.6%
FY25
A 21.3%
CRL 0.6%
A
CRL
FY16
A $654M
CRL $262M
FY17
A $713M
CRL $236M
FY18
A $910M
CRL $301M
FY19
A $866M
CRL $340M
FY20
A $802M
CRL $380M
FY21
A $1.3B
CRL $532M
FY22
A $1.0B
CRL $295M
FY23
A $1.5B
CRL $365M
FY24
A $1.4B
CRL $502M
FY25
A $1.2B
CRL $518M
A
CRL
FY16
A 14.5%
CRL 10.1%
FY17
A 17.7%
CRL 7.5%
FY18
A 10.9%
CRL 11.4%
FY19
A 19.0%
CRL 9.8%
FY20
A 12.5%
CRL 9.9%
FY21
A 19.3%
CRL 11.1%
FY22
A 19.8%
CRL 9.9%
FY23
A 17.9%
CRL 8.9%
FY24
A 16.9%
CRL 2.0%
FY25
A 16.5%
CRL 0.4%
A
CRL
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.